Hypertensive kidney disease: true epidemic or rare disease?

Authors: Tomasz Stompór, Agnieszka Perkowska-Ptasińska

Article type: Review article

Received: November 20, 2019.

Accepted: January 20, 2020.

Published online: January 22, 2020.

ISSN: 1897-9483

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.
Hypertensive kidney disease: true epidemic or rare disease?

Tomasz Stompór,¹ Agnieszka Perkowska-Ptasińska²,*

¹ Department of Nephrology, Hypertension and Internal Medicine, Medical Faculty, University of Warmia and Mazury, Olsztyn, Poland
² Department of Transplantology, Nephrology and Internal Diseases, Medical University of Warsaw, Poland

*Corresponding author
Agnieszka Perkowska-Ptasińska,
Associate Professor of Pathology
Department of Transplantology, Nephrology and Internal Diseases, Medical University of Warsaw, Poland
Street Nowogrodzka 59
02-005 Warsaw, Poland
aggape@poczta.onet.pl. Tel.: +48225021195

short title: Hypertensive kidney disease

Conflict of interest: none to declare.

Author Contributions: both authors equally contributed to the content of this paper and can be considered equally as first authors.

Funding: no external funding.
Abstract: In the industrialized world, hypertension affects approximately 30% of the general population. Hypertensive kidney disease is considered one of the consequences of long-term and poorly controlled hypertension. According to renal databases, it is a leading cause of end-stage renal failure, second only to diabetic kidney disease. We challenge this dogma by citing the lack of specificity of both clinical and morphological presentations of hypertension-related kidney disease and the very low prevalence of hypertensive kidney disease that is diagnoses based on kidney biopsy findings in registries. In most cases of concomitant hypertension and chronic kidney disease (CKD), the sequence of events (i.e., which came first, CKD or hypertension) cannot be established. Arterial hypertension plays a role in the pathogenesis of chronic vascular disease and may occasionally lead to arterionephrosclerosis, but its general significance in the evolution of CKD and prevalence among CKD patients appear to be highly overestimated. Studies of the morphology of kidney biopsies have indicated that arterionephrosclerosis, classically considered a morphological equivalent of the clinical term ‘hypertensive kidney disease’ (previously referred to as ‘hypertensive nephropathy’), most commonly superimposes upon variable chronic renal diseases, even in the absence of elevated blood pressure. To date, no prospective, controlled clinical trials have been conducted with primary hypertension patients with renal events as primary endpoints. Data from existing clinical trials with renal events that serve as secondary endpoints suggest that lowering blood pressure below actual targets may provide additional cardiovascular benefits but may be harmful to the kidneys.

Key words: arterionephrosclerosis, chronic kidney disease, hypertensive kidney disease, kidney biopsy, renal pathology
1. Introduction

The kidneys regulate body fluid status and sodium balance and release several blood pressure (BP)-regulating hormones that play an important role in the development of primary and secondary hypertension. The kidneys are also affected by high BP. However, accumulating evidence indicates that this complex interdependence of the kidneys should be considered the culprit rather than the victim of high BP. The present review discusses the true significance of so-called ‘hypertensive kidney disease’ (HKD; i.e., renal consequences of essential and secondary non-renal hypertension). Based on recent literature, with very few specific exceptions, we believe that such term should be abandoned.

2. Hypertensive kidney disease: definitions and epidemiology

The epidemiological dimension of HKD remains a subject of debate. Some researchers believe that this is a true epidemic, a frequent complication of, and the second most common cause (after diabetic kidney disease) of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Other researchers, however, deny the existence of such a diagnosis at all [1, 2]. Indeed, several classic studies of hypertension treatment (from the era when placebo could still be used as a control for active treatment) clearly demonstrated that long-term, poorly controlled hypertension damages the kidneys, and both BP and the duration of hypertension are correlated with the risk of CKD and ESRD. The same message comes from large cross-sectional and observational trials, in which renal damage is defined as a decrease in glomerular filtration rate (GFR), increase in serum creatinine, or the development of ESRD [3-5]. A more recent analysis by National Heart and Nutrition Examination Study found an association between the severity of hypertension and risk of an estimated GFR (eGFR) drop below 60 ml/min/1.73 m². A more detailed analysis showed that such a
relationship remains significant only in patients with concomitant urinary albumin to creatinine ratio of \( \geq 30 \) mg/g. No association between BP and CKD was observed below this threshold of the urinary albumin-creatinine ratio (UACR) [6]. The key argument that is made by authors who believe in “HKD epidemics” is that hypertension is the second most common cause (after diabetic kidney disease) of ESRD. Most renal registries state that up to 30% of all patients who are on renal replacement therapy developed ESRD because of HKD. This argument can be easily refuted by simply applying the strict definition of HKD. The classic definition (i.e., Schlessinger criteria) states that HKD is renal damage that develops in patients with long-term and poorly controlled hypertension, in which other causes of kidney disease are excluded (Table 1) [7]. However, in most patients who are given a diagnosis of HKD, these criteria are not met because the workup to exclude “other causes” is usually not performed. With the exception of a few situations in which a definitive diagnosis of renal pathology that leads to CKD can be established based on imaging techniques (e.g., polycystic kidney disease, vesico-urinary reflux, advanced bilateral renal artery stenosis, and staghorn nephrolithiasis) or a specific biomarker (e.g., metabolic errors with genetic background), the gold standard in the diagnosis of kidney disease is core biopsy. The vast majority of patients with advanced CKD and ESRD have never been biopsied; therefore, the true etiology of the disease cannot be defined. A similar epidemiological myth applies to diabetic kidney disease (DKD). Most patients with type 2 diabetes and any renal symptoms (e.g., albuminuria, proteinuria, elevated serum creatinine, and lower GFR) will be diagnosed with DKD, and DKD is considered the leading diagnosis in patients who start dialysis. The clinical diagnosis of DKD, however, cannot be established based on clinical signs or symptoms without kidney biopsy, which is not routinely performed in diabetic patients. The results of available studies suggest the overestimation of DKD as a sole cause of ESRD [8].
Most patients who undergo renal biopsy suffer from hypertension, but hypertension is almost never considered a single or leading indication for a biopsy. Interestingly, in large biopsy registries, HKD is reported sporadically or not reported at all (except in the United States, where it also does not in general exceed 8-10%), despite a high prevalence of hypertension in the general population and an even higher prevalence in patients with symptoms of kidney disease [9-12].

To increase the specificity of an HKD diagnosis, attempts were made to develop criteria that allowed recognition of this entity. Schlessinger criteria and the AASK criteria (i.e. criteria developed for use in the African-American Study of Kidney Disease and Hypertension) were designed for individuals of non-African and African descent, respectively (Table 1). The poor application of these criteria, however, was revealed by Zarif et al., who carefully analyzed medical histories of a multi-ethnic group of dialyzed patients with HKD that was diagnosed as the cause of ESRD [13]. Detailed analysis indicated that Schlessinger criteria were met in 1.5% and AASK criteria were met in 13.5% of the respective groups of patients. In many cases, studies of pre-dialysis medical data raised suspicions of renal diseases other than HKD, such as DKD, chronic glomerulonephritis, acute GN, interstitial nephritis, HIV-associated nephropathy, renal cell carcinoma, and even kidney myeloma. Renal biopsy results were available for only four patients, among whom there was one case in which morphologic picture could have corresponded to HKD [14]. These data, although very limited in size, illustrate the worldwide trend of labelling patients with HKD instead of trying to uncover the true cause of renal dysfunction. A total of 35-50% of patients who start renal replacement therapy are referred to renal care in less than 4 months before dialysis commences [14, 15]. In most of them, any attempt to establish a credible diagnosis of underlying kidney disease cannot be made. Hypertension is almost always present, and it is tempting to blame it as a cause of CKD, although the sequence of events
(e.g., hypertension first, followed by CKD, or vice versa) usually cannot be established. In
the United Kingdom, Finland, and Austria, the reported percentage of patients with
hypertension as an apparent cause of ESRD varies between 5% and 10% [16]. These
discrepancies in the reported frequency of HKD may be related to the influence of ethnicity
but appear to primarily reflect differences in the type and quality of healthcare systems [16].
The dimension of epidemics of HKD can be placed into the Polish context. Epidemiological
studies indicate that 30% of the overall Polish population suffer from hypertension (i.e., ~10
million individuals). It is officially reported that of all patients who undergo dialysis (~22,000
individuals), approximately 30% (~6,000-7,000 individuals) progressed to ESRD through
HKD. These numbers suggest that ESRD that is attributable to hypertension is an extremely
rare event (even after including kidney transplant recipients). This number is probably even
lower because of the presumed misclassification of many patients who are simply labeled
with a diagnosis of HKD without biopsy confirmation.

In summary, the true epidemic dimension of HKD cannot be credibly estimated.
However, with the exception of African American ethnicity and extreme cases of long-term,
severe, untreated, uncontrolled, or malignant hypertension, this entity as an isolated
phenomenon does not constitute an important cause of CKD, although hypertension
definitely contributes to the progression of CKD of any cause.

3. Pathogenesis of hypertension-related kidney damage

Under physiological conditions, intraglomerular pressure is relatively constant, at least in
the range of systemic systolic blood pressure (SBP) between 80 and 160 mmHg. The
adequate constriction of an afferent arteriole in response to BP rise (i.e., the mechanism of
autoregulation) protects the glomerulus from hypertension and also “smooths” the
systolic/diastolic difference in BP, thus guarding the glomerulus against pulsation. Indeed,
the systolic-to-diastolic change in glomerular volume is minimal. According to current knowledge, two distinct mechanisms of renal damage occur during the course of hypertension. In the first mechanism, autoregulatory properties of renal microcirculation are progressively lost, with resultant abnormal dilatation of the afferent arteriole and a secondary increase in intraglomerular pressure, paralleled by a rise in SBP. The direct transmission of hypertension from larger vessels to glomerular structures causes pulsation, stretching, and endothelial injury. Apart from oxidative stress, these hemodynamic changes activate the renin-angiotensin-aldosterone system (RAAS), nuclear factor κB (NF-κB) transcription, and the synthesis of profibrotic growth factors, the leading one of which is transforming growth factor β (TGFβ) [17,18].

The second mechanism is considered by some authors to be an alternative to the first mechanism but considered by other authors to simply be a second phase of the first mechanism. This mechanism may be recognized as an adaptive reaction of renal microcirculation with resultant arteriolar wall hypertrophy, lumen narrowing, and flow reduction. This mechanism may be compared to the development of pulmonary hypertension in response to greater blood flow in the pulmonary circulation that is caused by cardiac shunt or arterio-venous fistulas. Similar to the first mechanism, this second mechanism is strongly related to RAAS activation, greater endothelin 1 stimulation, and the expression of proinflammatory cytokines and profibrotic growth factors [19].

4. **Hypertensive kidney disease and arterionephrosclerosis: not equivalent terms**

HKD is a clinical and not morphological term. It is traditionally used to describe a syndrome that is characterized by long-term essential hypertension, hypertensive retinopathy, left ventricular hypertrophy, minimal proteinuria (usually of less than 0.5 g/d or urinary albumin-to-creatinine ration of less than 0.5 g/g), and progressive renal insufficiency. At the
microscopic level, HKD manifests as either an acute thrombotic microangiopathy that is caused by the accelerated/malignant phase of hypertension or a chronic arterinephroscclerosis process [20]. Arterinephroscclerosis is defined as a combination of arteriosclerosis (i.e., intimal fibrosis), accompanied by either media thickening (attributable to smooth muscle cell hyperplasia) or thinning (attributable to vascular wall remodeling or media atrophy), afferent arteriole hyalinization, secondary chronic glomerulopathy (ischemic or hypertrophic), and tubulointerstitial scarring (Fig. 1-3). The evolution of chronic glomerular lesions depends on the pattern of afferent arteriole hyalinization. In the obstructive type of hyaline deposition, glomeruli exhibit progressive ischemic lesions, manifested by evolving simplification of the glomerular tuft that is associated with wrinkling of the glomerular basement membrane (GBM), capillary collapse, and the distension of Bowman’s space (Fig. 2). In the other form, hyalinization is accompanied by arteriolar smooth muscle cell atrophy and secondary lumen dilatation, which lead to glomerular tuft hypertrophy. Dilatation of the afferent arteriole reflects an impairment in its myogenic response and loss of the autoregulation mechanism [21,22]. In both forms of glomerulopathies, the ultimate outcome is secondary tuft sclerotization, which is an obsolescent type in the case of ischemia (characterized by Bowman capsule preservation) and a solidified form (with Bowman capsule not preserved) as a complication of glomerulomegaly (Fig. 3) [23]. Ischemic glomerulopathy and the obsolescent type of glomerulosclerosis generally dominate, except in patients of African American descent, among whom glomerulomegaly and the solidified type of tuft sclerrotization are more common [24].

Arterinephroscclerosis is a disease of all renal tissue compartments. Blood is supplied to tubules and interstitial tissue by post-glomerular (efferent) arterioles, and glomerular ischemia leads to tubulointerstitial ischemia, which gradually translates into progressive interstitial fibrosis and tubular atrophy (Fig. 1). Additionally, proteins that leak through the
damaged glomerulus are reabsorbed by tubules, promoting tubulointerstitial scarring [20].

In the case of severe or malignant hypertension, its deleterious impact on the kidney is mostly seen in glomeruli, arterioles, and interlobular arteries. The lesions may vary in terms of severity, ranging from widening of the subendothelial region of the vascular wall (an ultrastructural phenomenon) to the fibrinoid necrosis of glomerular capillaries and arteriolar and arterial walls and the presence of thrombi (revealed by light microscopy). Additionally, with regard to the aforementioned lesions, a reduction of the vascular lumen may be complicated by glomerular ischemia, manifested by capillary collapse, GBM wrinkling and ultimately glomerulosclerosis. The other scenario that finalizes with the sclerotization of glomerular tuft is initiated by the increase of the filtration pressure that leads to mesangiolysis, glomerulomegaly and ultimately to so-called hypertrophic glomerulosclerosis. With time, also the non-glomerular acute lesions evolve into chronic ones: arteriolar hyalinization, and “onionskin” fibrotic thickening of the arteriolar and arterial walls.

Glomerular and vascular injury is initially accompanied by acute tubular epithelium injury, interstitial edema (with interstitial hemorrhage and necrosis in more severe cases), and a mild inflammatory reaction. In later phases, the tubulointerstitial compartment exhibits more or less extensive scarring [20].

The causal relationship between accelerated or malignant hypertension and kidney injury is usually quite apparent because they temporally coincide, and this relationship is further supported by the simultaneous evolution of retinopathy. Although most commonly discussed in the context of HKD, lesions that define the phenomenon of arterionephrosclerosis are nonspecific in nature and occur under various physiological and pathophysiological conditions.

Studies of peri-implantation kidney transplant biopsies have shown that arteriosclerosis and arteriolar hyalinization are common lesions in donor kidneys. They almost always occur
together and evolve in parallel, reflected by similar stages of progression [25].

Arteriosclerosis and arteriolar hyalinization have been reported to be strongly correlated with age and hypertension. However, analyses of donor kidney morphology have shown that they are generally not accompanied by tubulointerstitial or glomerular lesions that are typical of nephrosclerosis (Fig. 4) [25, 26]. Moreover, the relationship between the severity of these lesions and the risk of nephrosclerosis has not been confirmed.

The rare occurrence of arterionephrosclerosis as a dominant or isolated type of kidney injury, even in the elderly population, has been confirmed by data from kidney biopsy registries. Studies that analyzed the prevalence of kidney biopsy-based diagnoses showed that the proportion of cases in which arterionephrosclerosis is a dominant microscopic finding ranged from 0.7% in Polish cohorts to up to 3.4% in Czech cohorts [9,10, 27]. Among Polish elderly patients who underwent kidney biopsy, only 1.0% were diagnosed with arterionephrosclerosis, although as many as 80.6% of the patients aged ≥ 65 years suffered from hypertension [9]. According to other published kidney biopsy registries, the frequency of arterionephrosclerosis as a dominant/isolated pathology in elderly patients varies from 1.53% in Chinese cohorts to 7.1% in United States cohorts [28-30]. The fact that the prevalence of arterionephrosclerosis in the United States population is distinctly higher than in populations from other regions of the world is related to the greater susceptibility of African Americans to arterionephrosclerosis relative to Caucasians [24]. In African Americans, arterionephrosclerosis may even precede the occurrence of hypertension, demonstrating that it is a pure manifestation of genetic renovasculopathy in some instances (see below) [31]. To date, no studies have revealed any qualitative differences in the morphological characteristics of evolving arterionephrosclerosis during the course of long-term hypertension compared with age-related lesions in elderly patients with no history of high BP.
Advanced sclerotization of the intrarenal arteries (i.e., the major component of arterionephrosclerosis) is commonly present in various chronic nephropathies, even in the absence of hypertension. Various types of chronic glomerular injuries, such as diabetic glomerulopathy, immunoglobulin A nephropathy, membranous glomerulonephritis, disparate etiological forms of FSGS, and chronic interstitial inflammation, are commonly accompanied by severe chronic arterial lesions, even before the occurrence of hypertension [32]. At the time of end-stage renal insufficiency, both native and transplant kidneys almost always exhibit morphological features of arterionephrosclerosis, independent of the nature of the original kidney disease. Data indicate that chronic injurious processes enhance tissue aging, which may at least partially explain arterionephrosclerosis being a constant part of progressive kidney disease [33]. In conclusion, with the exception of patients in whom the clinically apparent episode of malignant hypertension is further confirmed by the morphological presentation of arterionephrosclerosis in kidney tissue, HKD cannot be unambiguously diagnosed based on kidney biopsy because of the lack of sensitivity and specificity of morphological findings.

5. Genetic factors in the development of HKD

Currently available methods for analyzing potential links between specific gene variants and disease phenotypes allow the identification of potential genetic backgrounds that predispose individuals to kidney damage that results from hypertension. One gene candidate is the gene that encodes uromodulin (UMOD; Tamm-Horsfall protein [THP]). The protein is considered kidney-specific because it is synthetized exclusively by epithelial cells of the thick ascending limb. This protein has several physiological functions, including the control of sodium-potassium-chloride co-transporter activity in this region of nephron, which might be relevant to BP regulation [34, 35]. Animal studies recently showed that THP gene knockout
or THP gene mutations were associated with the marked upregulation of RAAS and the development of oliguria and hypertension that are unresponsive to furosemide [36, 37]. Another gene candidate may be the gene that encodes MYH9. The A isoform of type II myosin heavy chain is an important structural component of the podocyte cytoskeleton. Abnormal MYH9 expression may promote foot process effacement (i.e., the universal sign of podocyte dysfunction or damage). Both the THP and MYH9 genes, in addition to the gene that encodes apolipoprotein L1 (APOL1), appear to affect the susceptibility of renal parenchyma to hypertension-related damage in patients of African descent. Certain MYH9 gene polymorphisms promote the development of renal damage in hypertensive African Americans, although its influence is much weaker than APOL1. Moreover, the influence of MYH9 gene polymorphisms nearly disappeared when controlled for APOL1 risk alleles [38].

A large study that analyzed the prevalence and progression of CKD showed a strong relationship between the risk of CKD onset, the rate of CKD progression, and APOL1 gene variants in African Americans [39]. Such a relationship was not observed among hypertensive Americans of European descent, in which the prevalence of risk alleles did not exceed 3% of the European Caucasian population [40]. Interestingly, variants of the APOL1 gene that increase the susceptibility to CKD were protective against Trypanosoma, an infection that is transmitted by tsetse (Glossina) flies in Sub-Saharan Africa.

APOL1 risk alleles have been reported to promote renal damage through several mechanisms, leading to primary FSGS, increasing the progression of renal damage in adaptive FSGS, promoting kidney injury in HIV-associated nephropathy, increasing the susceptibility of kidney tissue to interferon, and leading to the development of arterionephrosclerosis, which is considered a morphological characteristic of HKD [41, 42]. The link between APOL1 risk alleles and the development of distinct renal pathology has been identified, thus creating a new clinical entity, APOL1 nephropathy.
6. **Congenital low nephron number as a factor that programs the development of hypertension and CKD**

Congenitally low nephron number and low renal mass are considered major determinants of the future development of hypertension or CKD. Histomorphometric analysis indicated that the number of nephrons in apparently healthy people may vary between 200,000 to more than 2.5 million per kidney. Autopsy-based studies have shown that a low nephron number is associated with the development of hypertension (which is usually sodium-dependent), hyperfiltration, proteinuria, and the occurrence of CKD [43, 44]. A low nephron number at birth is also linked to a higher risk of being overweight, obesity, metabolic syndrome, and diabetes later in life. Final development of the kidney and the establishment of nephron number occur late in the last trimester of pregnancy. Therefore, key risk factors of low nephron number at birth (also referred to as “nephron underdosing” or oligonephronia) include prematurity and intrauterine growth retardation. These two conditions, in turn, depend on several socioeconomic and medical factors, including suboptimal prenatal care, maternal nutrition deficits, smoking, alcohol intake, drug abuse, low vitamin A status, infection, hypertension, CKD, gestational diabetes mellitus, and genetic background [45, 46].

Up to 15% of all neonates are small for gestational age, and up to 10% of all deliveries are premature. Therefore, fetal programming may be an important risk factor for hypertension and CKD in the general population. Many of these adverse outcomes remain preventable with improved prenatal care. Interestingly, some studies questioned the importance of glomerular number for the development of renal damage secondary to hypertension, at least in African Americans. Glomerular volume rather than glomerular number was identified as an independent risk factor for the development of renal damage in patients with hypertension [47].
7. Treatment of hypertension and HKD

Interestingly, current European guidelines on the detection and treatment of high BP now recommend less tight control of BP in patients who suffer from CKD as compared to other patient groups. The universal goal of SBP < 130 mmHg and diastolic BP (DBP) between 70 and 79 mmHg has been established. Target SBP is set at 130-139 mmHg in individuals who are ≥ 65 years old. Maintaining these target values is believed to prevent end-organ damage (including kidney protection) with the simultaneous avoidance of untoward adverse effects of treatment. The European Society of Cardiology (ESC) and European Society of Hypertension (ESH) guidelines accept more liberal targets of BP control also in subjects with established CKD (i.e., SBP of 130-139 mmHg for all age ranges) [48]. RAAS blocking agents are currently considered the treatment of choice not only for patients with hypertension and concomitant albuminuria or proteinuria but also for all patients with hypertension. Patients who use two or more BP-lowering drugs should be treated with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin II receptor type 1 blocking agents (ARB), unless contraindicated. In other hypertension patients, starting monotherapy can sometimes be attempted. In patients with established CKD, the initial treatment should always consist of two drugs, which must include either an ACEi or ARB [48]. Recent United States guidelines, endorsed by many key medical associations, including the American Heart Association, suggest achieving a universal target BP < 130/80 mmHg, independent on any comorbidity, age group, etc. [48]. These criteria apply to all patients with a calculated 10-year risk of cardiovascular disease of ≥ 10% [50]. According to experts from the Kidney Disease: Improving Global Outcomes (KDIGO) expert panel, patients with proteinuria > 30 mg/day are suggested to maintain BP values ≤ 130/80 mmHg [49]. Patients with albuminuria that ranges from 30 to 300 mg/day are recommended to use RAAS blocking agents. This turns
into a stronger recommendation once albuminuria exceeds 300 mg/day [50]. According to all available guidelines, double RAAS blockade is contraindicated (e.g., ACEi, ARBs and direct renin inhibitors in any combination). In patients with albuminuria of less than 30 mg/day no first-choice BP-lowering drug is specified. Theoretically, dihydropyridine-type calcium channel blockers (DHP-CCBs) are not best suited for the initial treatment of hypertension in the setting of renal disease because they additionally dilate the afferent arteriole. However, no long-term trials have reported the inferiority of this drug group with regard to kidney function protection, aside from studies that used indirect (surrogate) renal outcome measures, such as a reduction of albuminuria. Additionally, cardiovascular protection is the number one priority in the treatment of hypertension. Thus, comorbidities other than CKD would usually dictate the choice of drugs [50]. Table 2 presents the summary of selected guidelines dealing with target BP values in patients with CKD.

Chronic kidney disease is a frequent cause of treatment-resistant hypertension. A total of 20-30% of all patients with hypertension experience resistance to treatment, and this percentage rises to 80-90% in patients with advanced CKD, which is inversely correlated with the loss of GFR and parallels an increase in proteinuria (albuminuria) [51]. Thus, debates about the choice of the third drug (assuming ACEi/ARB + CCB or a diuretic are the first choice) are purely academic. Most hypertensive patients with CKD will receive three drugs from the aforementioned list. Any other drug that is added to this regimen should be based on general rules of hypertension treatment. Unfortunately, in more advanced CKD, the use of a preferred “number 4” drug, spironolactone, is commonly limited by the risk of hyperkaliemia.

8. Impact of BP control in essential hypertension on the development of CKD and patient survival
To our knowledge, no clinical studies have evaluated the impact of essential hypertension control with the development of CKD as a primary endpoint (i.e., the primary prevention of CKD in essential hypertension). The only published clinical trial in which CKD progression served as a primary endpoint for assessing the effectiveness of BP-lowering therapy in hypertensive African American patients with already established CKD (i.e., secondary prevention) was the AASK study [52]. One key finding of the AASK trial was that intensive BP lowering did not inhibit the rate of CKD progression. No difference was detected in the rate of GFR loss between patients who were randomized to therapeutic arms with DHP-CCB, a β-blocker, or an ACEi [52]. The only renal benefit was found in patients with baseline proteinuria who were treated with a RAAS inhibitor, which is a common finding in trials that are devoted to nephroprotection. Interestingly, among African American patients, the effectiveness of BP-lowering drugs was independent of APOL1 risk allele status [38]. The AASK study may pave the way toward new thinking about the relationship between kidney disease and hypertension in an attempt to resolve the “chicken-or-egg” dilemma. Originally designed to demonstrate protection against renal consequences of primary hypertension, The AASK study turned into a key study that demonstrated that primary kidney disease (i.e., APOL1 risk allele-triggered arterionephrosclerosis) precipitates the onset of hypertension. A similar conclusion emerged from a meta-analysis of 11 trials that included 5308 patients with cryptogenic or non-hypertensive CKD upon enrollment. Additional SBP lowering of 7.7 mmHg and DBP lowering of 4.9 mmHg compared with standard BP targets did not influence the rate of CKD progression in patients without proteinuria, whereas it reduced the risk of progression by 27% in patients with protein loss > 300 mg/day or > 0.22 g/g of urine creatinine. One should however interpret these data very cautiously since the studies included into this meta-analysis comprised very diverse patient groups (i.e. children, older patients, African American subjects from AASK, diabetics and
patients without diabetes; importantly, all were diagnosed with CKD) [53]. Additionally, tight BP control reduced albuminuria or the rate of GFR loss. In patients with established baseline CKD, however, tight BP control had little impact on the cardiovascular or cerebrovascular event rate or overall survival [53]. Some studies, however, reported that BP-lowering interventions may be equally effective in preventing cardiovascular events also in patients with a lower baseline GFR. This was further demonstrated in another meta-analysis of 25 prospective hypertension trials that included 152,900 CKD patients. Both groups (i.e., subjects with and without CKD) experienced similar benefits in terms of lower mortality and fewer cardiovascular events, regardless of baseline CKD status and eGFR level. This benefit did not depend on the type of BP-lowering drug that was used or the presence or absence of proteinuria. Notably, however, the vast majority of CKD patients were in CKD stages 1-3 (i.e., eGFR > 30 ml/min/1.73 m²). Patients with eGFR lower than 30 ml/min/1.73 m² contributed to the overall study sample in only 0.3% [54].

One of the most important recent clinical hypertension studies was the Systolic Blood Pressure Intervention Trail (SPRINT). This trial provided new arguments to the ongoing discussion of target BP values in different populations and significantly influenced the recent United States guidelines for hypertension treatment. The SPRINT study showed that aggressive BP management had a significant beneficial effect on all-cause mortality, cardiovascular mortality, and heart failure rate but was also associated with a significant reduction of eGFR, with the risk of kidney function worsening being 3.49-times higher in patients with target SBP < 120 mmHg as compared to patients whose target BP was established at the level of 135-140 mmHg [55]. The findings of the SPRINT trial may not be fully applicable to most of hypertensive patients due to unique method of BP assessment (i.e. unattended automatic blood pressure measurement that virtually eliminated the ‘white coat’ effect). The substantial difference in BP between routine and automatic unattended BP
assessment was also confirmed by other authors [56].

One long-lasting dogma in nephrology is that albuminuria reduction equates with nephroprotection. Indeed, in the natural evolution of many kidney diseases, albuminuria/proteinuria precedes a reduction of GFR. In many cases, though the gradual loss of GFR is not preceded or even accompanied by urine protein loss. The dynamics of the eGFR reduction (usually 25% or 50% relative to baseline), the time to doubling baseline serum creatinine, or reaching a eGFR < 45 or 15 ml/min/1.73 m² (n.b., the latter is considered equivalent to ESRD) seem to better define the CKD progression. A drop in urine albumin loss may simply reflect a hemodynamic effect of certain drugs that lower intra-glomerular pressure (e.g., RAAS inhibiting agents – ACEi, ARB). In several prospective randomized trials, subsequent to BP lowering albuminuria reduction was not followed by a decrease in the rate of GFR drop [57-60]. The results of the ACCOMPLISH (The Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension) trial showed that more pronounced effect of antihypertensive therapy on GFR loss and the rate of cardiovascular events was associated with lower efficacy with regard to reducing albuminuria and vice versa [62]. These findings were codified by a joint conference of experts from the Food and Drug Administration and National Kidney Foundation, who recommended to not equate a reduction of albuminuria with nephroprotection [62].

9. Conclusions

The true prevalence, diagnostic criteria, prevention, and treatment of HKD are poorly defined. Hypertensive kidney disease became a popular label for patients with CKD in whom proper diagnostic tests of renal disease were not performed or in whom the disease was difficult to define because of the multifactorial nature of kidney tissue damage. With the exception of patients in whom the clinically apparent episode of malignant hypertension is
further confirmed by the morphological presentation of arterionephrosclerosis in kidney biopsies, HKD cannot always be unequivocally diagnosed even based of microscopic examination, but kidney biopsy is always helpful for at least narrowing the differential diagnosis. Currently we are not able to formulate any indications to perform kidney biopsy in patients with essential hypertension and renal involvement extending beyond ‘classical’ indications based on urine sediment findings, proteinuria/albuminuria and GFR. It is however of paramount importance to promote ‘liberal’ approach to kidney biopsy, for example, not to postpone it even in patients with mild, otherwise unexplained proteinuria. Non-invasive assessment of kidney disease should certainly be also considered. For example, patients with long-lasting, poorly controlled essential hypertension can be subjected to functional magnetic resonance imaging (fMRI) – the growing body of evidence indicates the relationship between fMRI findings and features of kidney damage on microscopic assessment and even an insight into renal metabolism provided by this technique (although such a relationship still awaits validation) [63]. Another technique that holds promise in non-invasive assessment of renal damage is an ultrasound-based analysis of intra-renal blood flow that seems to be ideally suited for an assessment of kidney vasculature [64]. Finally, it seems that we enter the new era of nephroprotection due to the increasing role of sodium-glucose co-transporter type 2 inhibitors (SGLT2i) in therapy. These drugs, initially developed to lower glucose in patients with poorly controlled type 2 diabetes, have also been demonstrated to protect from cardiovascular events and mortality in patients with and without diabetes, and are also used to improve blood pressure control in patients with well-controlled diabetes (not as glucose-lowering, but as BP-lowering drugs). Given the wide range of nephro- and cardio-protective mechanisms one can expect that SGLT2i will shape the new future of patients with hypertension and kidney disease with or without diabetes [65-67].
References:
1. Hughson MD, Puelles VG, Hoy WE, et al. Hypertension, glomerular hypertrophy and nephrosclerosis: the effect of race. Nephrol Dial Transplant. 2014; 29: 1399-409.
2. US Renal Data System. National Institute of Diabetes and Digestive and Kidney Disease. USRDS 2016 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. https://www.usrsds.org/adr.aspx.
3. Walker WG, Neaton JD, Cutler JA, et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992; 268: 3085-3091.
4. Young JH, Klag MJ, Muntner P, et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol. 2002; 13: 2776-2782.
5. Tozawa M, Iseki K, Iseki C et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003; 41: 1341-1345.
6. Yan P, Zhu X, Li H, et al. Association of high blood pressure with renal insufficiency: role of albuminuria, from NHANES, 1999-2006. PLoS One 2012; 7: e37837.
7. Schlessinger SD, Tankersley MR, Curtis JJ: Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis. 1994; 23:655-660.
8. Sharma SG, Bomback AS, Radhakrishnan J, et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol. 2013; 8: 1718-1724.
9. Perkowska-Ptasinska A, Bartczak A, Wagrowska-Danilewicz M, et al. Clinicopathologic correlations of renal pathology in the adult population of Poland. Nephrol Dial Transplant. 2017; 32 (suppl. 2): ii209-ii218.
10. Maixnerova D, Jancova E, Skibova J, et al. Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994-2011. J Nephrol. 2015; 28: 39-49.
11. Jin B, Zeng C, Ge Y, et al. The spectrum of biopsy-proven kidney diseases in elderly Chinese patients. Nephrol Dial Transplant. 2014; 29: 2251-2259.
12. Yokoyama H, Sugiyama H, Sato H, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012; 16: 903-920.
13. Zarif L, Covic A, Iyengar S et al. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant. 2000; 15: 1801-1807.
14. Hommel K, Madsen M, Kamper AL. The importance of early referral for the treatment of chronic kidney disease: a Danish nationwide cohort study. BMC Nephrol. 2012; 13: 108-116.
15. Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010; 14: 1-184.
16. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382: 260-272.
17. Riser BL, Cortes P, Zhao X, et al. Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest. 1992; 90: 1932-1943.
18. Riser BL, Varani J, Cortes P, et al. Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence: a possible new mechanism for glomerulosclerosis. Am J Pathol. 2001; 158: 11-17.
19. Mennuni S, Rubatu S, Pierelli G et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014; 28: 74-79.
20. Olson JL. Renal Disease Caused by Hypertension. In: Jennette JCH, Olson JL, Silva FG, Agati VD, eds. Heptinstall’s Pathology of the Kidney, 7th edition. Philadelphia: Wolters Kluwer; 2015: 854-863.
21. Just A. Mechanisms of renal blood flow autoregulation: dynamics and contributions. Am J Physiol Regul Integr Comp Physiol. 2007; 292: R1–R17.
22. Bidani AK, Polichnowski AJ, Loutzenhiser R, Griffin KA. Renal microvascular dysfunction, hypertension and CKD progression. Curr Opin Nephrol Hypertens. 2013; 22: 1-9.
23. Hill GS. Hypertensive nephrosclerosis. Current Opinion in Nephrology and Hypertension 2008, 17: 266–270.
24. Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002; 62: 172-118.
25. Wazna E, Pazik J, Perkowska-Ptasińska A, et al. Arteriolar hyalinization in implantation kidney biopsies as a predictor of graft function. Transplant Proc. 2009; 41: 2975-2977.
26. Tracy RE, Malcom GT, Oalman MC, et al. Renal microvascular features of hypertension in Japan, Guatemala, and the United States. Arch Pathol Lab Med 1992; 116: 50–55.
27. Moutzouris DA, Herlitz L, Appel GB, et al. Renal biopsy in the very elderly. Clin J Am Soc Nephr. 2009; 4: 1073-1082.

28. Jin B, Zeng C, Ge Y, et al. The spectrum of biopsy-proven kidney diseases in elderly Chinese patients. Nephrol Dial Transplant. 2014; 29: 2251-2259.

29. Yokoyama H, Sugiyama H, Sato H, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012; 16: 903-920.

30. Harmankaya O, Okuturlar Y, Kocoglu H, et al. Renal biopsy in the elderly: a single-center experience. Int Urol Nephrol. 2015; 47: 1397-1401.

31. Chang J, Ma JZ, Zeng Q, et al. Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). Am J Physiol Renal Physiol 2013; 304: F348–F355.

32. Meyrier A, Simon P, Montseny JJ, et al. Vascular Nephropathies and Nephrosclerosis. Epidemiology and Patho-physiology. In: Grllinfeld JP, Bach JF, Kreis H, Maxwell MH, eds. Advances in Nephrology. Chicago, Mosby - Year Book; 1996:207-245.

33. Jose SS, Bendickova K, Kepak T, et al. Chronic Inflammation in Immune Aging: Role of Pattern Recognition Receptor Crosstalk with the Telomere Complex? Front Immunol. 2017; 8: 1078-1088.

34. Trudu M, Janas S, Lanzani C, et al. Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med. 2013; 19: 1655-1660.

35. Tu W, Pratt JH. A consideration of genetic mechanisms behind the development of hypertension in blacks. Curr Hypertens Rep. 2013; 15: 108-113.

36. Liu Y, Goldfarb D, El-Achkar TM, et al. Tamm-Horsfall Protein/Uromodulin Deficiency Elicits Tubular Compensatory Responses Leading to Hypertension and Hyperuricemia. Am J Physiol Renal Physiol. 2018; 314: F1062-F1076.

37. Ma L, Liu Y, Landry NK, et al. Point mutation in D8C domain of Tamm-Horsfall protein/uromodulin in transgenic mice causes progressive renal damage and hyperuricemia. PLoS One. 2017; 12: e0186769.

38. Lipkowitz MS, Freedman BI, Langefeld CD, et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int. 2013; 83: 114-120.

39. Sica DA. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned? J Clin Hypertens (Greenwich). 2003; 5: 159-167.
40. Parsa A, Kao WH, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013; 369: 2183-2196.

41. Heymann J, Winkler CA, Hoek M, et al. Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte. Nephrol Dial Transplant. 2017; 32(suppl_1): i65-i70.

42. Madhavan SM, O'Toole JF, Konieczkowski M et al. APOL1 localization in normal kidney and nondiabetic kidney disease. J Am Soc Nephrol. 2011; 22: 2119-2128.

43. Keller G, Zimmer G, Mall G, et al. Nephr on number in patients with primary hypertension. N Engl J Med. 2003; 348: 101-108.

44. Wang X, Garrett MR. Nephr on number, hypertension, and CKD: physiological and genetic insight from humans and animal models. Physiol Genomics. 2017; 49:180-192.

45. Luyckx VA, Bertram JF, Brenner BM, et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet. 2013; 382: 273-283.

46. Luyckx VA, Perico N, Somaschini M, et al. A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. Lancet. 2017; 390: 424-428.

47. Hughson MD, Puelles VG, Hoy WE, et al. Hypertension, glomerular hypertrophy and nephrosclerosis: the effect of race. Nephrol Dial Transplant. 2014; 29: 1399-409.

48. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021-3104.

49. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACP/M/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2018; 71: e127-e248.

50. KDIGO Clinical Practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012; 2: 337–414.

51. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008; 52: 1749-1757.

52. Appel LJ, Wright JT Jr, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010; 363: 918-929.

53. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013; 185: 949-957.
54. Blood Pressure Lowering Treatment Trialists’ Collaboration, Ninomiya T, Perkovic V, Turnbull F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013; 347: f5680-5695.
55. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373: 2103-2116.
56. Filipovský J, Seidlerová J, Kratochvíl Z, et al. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press. 2016; 25: 228-234.
57. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013; 369: 1892-1903.
58. Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364: 907-917.
59. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012; 367: 2204-2213.
60. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372: 547-553.
61. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010; 375: 1173-1181.
62. Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the national Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009; 54: 205-226.
63. Selby NM, Blankestijn PJ, Boor P, et al. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action (PARENCHIMA). Nephrol Dial Transplant. 2018: 33: ii4 – ii14.
64. Januszewicz M, Januszewicz A, Michałowska I, et al. Association of intrarenal blood flow with renal function and target organ damage in hypertensive patients with fibromuscular dysplasia: the ARCADIA-POL study. Pol Arch Intern Med. 2019; 129: 234-241.
65. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373; 2117-2128.

66. McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019. 381; 1995-2008.

67. Kario K, Okada K, Kato M, et al. 24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study. Circulation. 2019. in press.

68. Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018. 71; e13-e115.

69. James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014. 311; 507-520.

70. Nerenberg KA, Zarnke KB, Leung AA, et al; Hypertension Canada. Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children. Can J Cardiol. 2018. 34; 506-525.

71. Hypertension in adults: diagnosis and management. NICE guideline [NG136] https://www.nice.org.uk/guidance/ng136

72. Chronic kidney disease in adults: assessment and management. Clinical guideline [CG182] https://www.nice.org.uk/guidance/cg182/chapter/1#pharmacotherapy

73. KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012. 2; 337 -415.
### Table 1. Clinical criteria for diagnosis of hypertensive kidney disease

| Schlessinger criteria                                                                 | AASK (apply to African-Americans)                          |
|--------------------------------------------------------------------------------------|------------------------------------------------------------|
| Family history of hypertension (first degree relatives)                              | Age 18 - 70 years                                          |
| Left ventricular hypertrophy (found in echocardiography or ECG)                      | Diastolic blood pressure >95 mmHg                          |
| Proteinuria less than 0.5 g/d in urinalysis or max. ++ in dipstick test              | Urine protein-to-creatinine ratio < 2.0 g/g                |
| Long-term hypertension with BP exceeding 140/90 mmHg before the onset of proteinuria and/or serum creatinine >1.2 mg/dl | No evidence of clinically relevant kidney disease with immunological background and/or diabetes |
| No history of exposition to nephrotoxic agents or known, clinically relevant kidney disease |                                                            |

Abbreviations: AASK: African-American Study of Kidney Disease and Hypertension; BP: blood pressure; ECG: electrocardiography.
Table 2. Blood pressure targets in patients with chronic kidney disease according to current guidelines.

| Guideline                                                                 | Year published | Office blood pressure (mmHg) |   |   |
|--------------------------------------------------------------------------|---------------|------------------------------|---|---|
| European Society of Cardiology/European Society of Hypertension [48]     | 2018          | 130 – 139                    | 70 - 79 |
| American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [68]*** | 2018          | < 130                        | < 80   |
| Joint National Committee (JNC) 8 [69]*                                   | 2014          | < 140                        | < 90   |
| Hypertension Canada (non-diabetic CKD) [70]                              | 2018          | < 140                        | < 90   |
| Hypertension Canada (all diabetics) [70]                                 | 2018          | < 130                        | < 80   |
| National Institute of Health and Care Excellence (NICE): CKD without diabetes and/or albuminuria [71,72] | 2019***       | 120 - 139                    | < 90   |
| National Institute of Health and Care Excellence (NICE): CKD with diabetes and/or albumin-to-creatinine ration of ≥70 mg/mmol [71,72] | 2019***       | 120 - 129                    | < 80   |
| KDIGO (no albuminuria) [73]                                              | 2012          | ≤ 140                        | ≤ 90   |
| KDIGO (albuminuria >30 mg/24 hours) [73]                                 | 2012          | ≤ 130                        | ≤ 80   |

Abbreviations: CKD: chronic kidney disease; KDIGO: Kidney Disease: Improving Global Outcomes

*Target BP do not differ in CKD vs no-CKD populations. In all remaining guidelines targets for CKD are different as compared to general population

**Targets recommended if concomitant known CVD or 10-year atherosclerotic cardiovascular disease (ASCVD) risk of 10% or higher; if no additional markers of increased CVD risk – targets may be reasonable. CKD, particular values of: GFR, serum creatinine or proteinuria not included into risk ACC/AHA risk calculator

*** 2019 NICE guidelines on hypertension do not discuss BP targets in CKD, but refer the reader to the CKD guidelines published in 2014 (last updated in 2017, but without change in BP targets).
Fig. 1. Arterionephrosclerosis.

Significant arterial lumen reduction due to the presence of fibrotic neointima (arrow). Severe tubulointerstitial scarring related to chronic ischemia. Trichrome stain. Original magnification x100.
Fig. 2. **Chronic glomerular ischemia.**
Glomerular tuft simplification, capillary collapse, GBM wrinkling (arrow), Bowman space extension. Silver stain. Original magnification x400.

Fig. 3. **Arteriolar hyalinization and global glomerulosclerosis.**
3a. Global glomerulosclerosis, obsolescent type with preserved Bowman capsule (arrow), 3b. Solidified type. Arteriolar hyalinization (arrowheads). Pas stain. Original magnification x200.
Fig. 4. Arteriosclerosis.
Despite intimal fibrosis (arrow) and arterial lumen reduction tubulointerstitial and glomerular morphology is preserved. Donor kidney. Trichrome stain. Original magnification x400.